Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 20/20 | 0.71 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.65 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29642860 | 1.00 | CFTR (0.71) | CFTRGABRA1TMEM97SIGMAR1 | |
| SCHEMBL19469593 | 1.00 | CFTR (0.71) | CFTRGABRA1TMEM97SIGMAR1 | |
| SCHEMBL19469597 | 1.00 | CFTR (0.71) | CFTRGABRA1TMEM97SIGMAR1 | |
| SCHEMBL17709141 | 0.95 | CFTR (0.75) | CFTRGABRA1TMEM97SIGMAR1 | |
| SCHEMBL17709089 | 0.95 | CFTR (0.75) | CFTRGABRA1TMEM97SIGMAR1 | |
| SCHEMBL17708735 | 0.92 | CFTR (0.68) | CFTRGABRA1TMEM97SIGMAR1 | |
| SCHEMBL29642784 | 0.92 | CFTR (0.68) | CFTRGABRA1TMEM97SIGMAR1 | |
| SCHEMBL19469577 | 0.92 | CFTR (0.68) | CFTRGABRA1TMEM97SIGMAR1 | |
| SCHEMBL19469575 | 0.92 | CFTR (0.68) | CFTRGABRA1TMEM97SIGMAR1 | |
| SCHEMBL19469579 | 0.92 | CFTR (0.68) | CFTRGABRA1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190055229-A1 | Heteroaryl Substituted Pyridines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2019-02-21 | — | — | US | claimed |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | ABBVIE S.Á.R.L. (LU) | 2017-10-26 | — | — | US | claimed |
| US-20240043386-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL ENTPR LTD (BM) | 2024-02-08 | — | — | US | disclosed |
| WO-2022150173-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Global Enterprises Ltd. (BM) | 2022-07-14 | — | — | WO | disclosed |
| US-20220213041-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | AbbVie Global Enterprises Ltd. (BM) | 2022-07-07 | — | — | US | disclosed |
| US-20220211692-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | AbbVie Global Enterprises Ltd. (BM) | 2022-07-07 | — | — | US | disclosed |
| EP-3865474-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2021-08-18 | — | — | EP | disclosed |
| EP-3736267-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| EP-3736270-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| US-10988454-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-27 | — | — | US | disclosed |
| US-10981890-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-20 | — | — | US | disclosed |
| US-10604515-B2 | Heteroaryl substituted pyridines and methods of use | ABBVIE S.Á.R.L. (LU) | 2020-03-31 | — | — | US | disclosed |
| EP-3464282-A1 | HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE | AbbVie S.À.R.L. (LU) | 2019-04-10 | — | — | EP | disclosed |
| US-20190077784-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2019-03-14 | — | — | US | disclosed |
| US-20190055229-A1 | Heteroaryl Substituted Pyridines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2019-02-21 | — | — | US | disclosed |
| US-10138227-B2 | Heteroaryl substituted pyridines and methods of use | ABBVIE S.Á.R.L. (LU) | 2018-11-27 | — | — | US | disclosed |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | ABBVIE S.Á.R.L. (LU) | 2018-11-06 | — | — | US | disclosed |
| US-20170349576-A1 | HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE | ABBVIE S.Á.R.L. (LU) | 2017-12-07 | — | — | US | disclosed |
| WO-2017208115-A1 | HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2017-12-07 | — | — | WO | disclosed |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | ABBVIE S.Á.R.L. (LU) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213041-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SLC47A2 | CFTR 1/4885GABRA1 964/4885TMEM97 93/4885 |
| US-20190077784-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | CFTR 1/4885GABRA1 1220/4885TMEM97 187/4885 |
| US-20240043386-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SLC47A2 | CFTR 1/4885GABRA1 964/4885TMEM97 93/4885 |
| US-20170349576-A1 | HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE | CFTR, P2RX2, P2RX1 | CFTR 1/4885GABRA1 1533/4885TMEM97 922/4885 |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | CFTR, CHRM2, CHRM1 | CFTR 1/4885GABRA1 2211/4885TMEM97 192/4885 |
| US-10604515-B2 | Heteroaryl substituted pyridines and methods of use | CFTR, P2RX2, P2RX1 | CFTR 1/4885GABRA1 1533/4885TMEM97 922/4885 |
| US-20190055229-A1 | Heteroaryl Substituted Pyridines and Methods of Use | CFTR, P2RX2, P2RX1 | CFTR 1/4885GABRA1 1533/4885TMEM97 922/4885 |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | CFTR, CHRM2, CHRM1 | CFTR 1/4885GABRA1 2211/4885TMEM97 192/4885 |
| US-10988454-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | CFTR 1/4885GABRA1 1220/4885TMEM97 187/4885 |
| US-10981890-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | CFTR 1/4885GABRA1 1220/4885TMEM97 187/4885 |
| US-20220211692-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SCNN1B, SLC47A2 | CFTR 1/4885GABRA1 1135/4885TMEM97 87/4885 |
| US-10138227-B2 | Heteroaryl substituted pyridines and methods of use | CFTR, P2RX2, P2RX1 | CFTR 1/4885GABRA1 1533/4885TMEM97 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.